According to MarketsandMarkets™, the Biomarkers Market is projected to grow from about USD 67.95 billion in 2026 to USD 112.10 billion by 2031, at a CAGR of 10.5%.

A successful partnership between Pitt’s BioForge subsidiary and a New York-based biotech startup has kept the latter in Pittsburgh. In an interview with the Business Times, their CEOs explained why.

According to MarketsandMarketstm, the Biomarkers Market is projected to grow from about USD 67.95 billion in 2026 to USD 112.10 billion by 2031, at a CAGR of 10.5%. Browse 690 market data Tables and ...

Terrestrial Bio has dosed the first patients in a Phase I clinical trial evaluating its patch that delivers GLP-1 therapeutic ...

PS, designed entirely by artificial intelligence, passed its first human safety trial at Cambridge — triggering ...

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe ...

Adults with house dust mite allergy may lose allergen-specific antibodies over time, and this decline is associated with ...

MtoZ Biolabs provides PhIP-Seq analysis support for antigen epitope screening, antibody repertoire profiling, autoantibody discovery, and biomarker research. BOSTON, MA, UNITED STATES, June 21, 2026 / ...

As genetic testing becomes increasingly important in modern healthcare, cytogenetics is emerging as a promising career for ...

Raphas, a mass-production platform company specializing in microneedle technology, has teamed up with Japanese electronics ...

Creative Biolabs’ integrated workflow addresses challenges in anti-glycopeptide antibody discovery, including weak ...